References in periodicals archive ?
s LevoDromoran, had been unavailable for most of the preceding year and is not expected to gain necessary FDA approvals to be back on the market for 12 to 18 months, he points out.
s LevoDromoran, the product is indicated for managing pain in cases in which an opioid analgesic is important.